| Execution period | 5 years |
|---|
NSE filing, NSE: GLAND. Summary written from the filing by ALFA Finder's alert engine.
Gland Pharma Ltd: key numbers
- Share price
- ₹3,049.00
- Market cap
- ₹50,312 Cr
- Revenue (annual)
- ₹6,431 Cr
- Net profit (annual)
- ₹1,027 Cr
- P/E (TTM)
- 44.6×Sector 46.1×
- Promoter holding
- 45.75%-6.02% QoQ
- FII holding
- 10.36%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gland Pharma Ltd
All →Gland Pharma Business Update
Gland Pharma reports that USFDA concluded an unannounced cGMP inspection at its Dundigal formulation facility with four procedural Form 483 observations. No monetary impact is stated, and corrective actions will be submitted within the stipulated period.
Gland Pharma Board Meeting Date
Gland Pharma Ltd scheduled a board meeting for November 06, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ending September 30, 2026.
Gland Pharma Other Announcement
Gland Pharma Limited has filed the confirmation certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.
Gland Pharma Annual General Meeting
Gland Pharma issued a postal ballot notice to seek shareholder approval for appointing Mr. Xingli Wang as Non-Executive Director. E-voting runs October 7 to November 5, 2026.
Gland Pharma Management Change
Gland Pharma Limited announced the resignation of director Wenjie Zhang and the appointment of Xingli Wang as a Non-Executive Non-Independent Director effective October 1, 2026.
Gland Pharma Acquisition Worth ₹199.5 Cr
Gland Pharma Limited's board approved a USD 21 million investment in its subsidiary, Gland USA, to acquire a 60% stake in Novelstar Pharma Inc. This acquisition facilitates business expansion in the USA.
- Value
- ₹199.5 Cr
- Execution
- By October 31, 2026
Other management change announcements
All →Hexaware Technologies Management Change
Hexaware appointed Arjun Shah and Gregory Zeluck as Non-Executive Directors from 28 October 2026. Directors Neeraj Bharadwaj and Julius Genachowski resigned, and Girish Pai's resignation is effective 13 November 2026.
GMR Airports Management Change
GMR Airports appointed Sanjeev Gupta as Executive Director (Deputy CEO) effective 29 October 2026. Non-Executive Director Alexis Riols resigned effective 28 October 2026.
Raymond Realty Management Change
Raymond Realty said joint statutory auditor Chaturvedi & Shah LLP resigned on 28 October 2026 after a dispute over audit fee revision. Walker Chandiok & Co LLP continues as the other statutory auditor.
Aarti Pharmalabs Management Change
Aarti Pharmalabs accepted CFO Piyush Lakhani's resignation, effective 30 October 2026, and appointed Vibha Thakker as CFO from 31 October 2026. The filing records a senior management change with no monetary amount.
TruCap Finance Management Change
TruCap Finance designated three employees as Senior Management Personnel, effective 29 October 2026. The changes are additional charges for Product, Operations and Contact Centre roles.
Sayaji Hotels (Indore) Management Change
Sayaji Hotels (Indore) appointed Azhar Yusuf Dhanani as Additional Non-Executive Non-Independent Director effective October 28, 2026. Shareholder approval is required within three months.